FDA approves Mylan’s generic Kytril

PITTSBURGH Mylan has received approval from the Food and Drug Administration for its application for a generic version of Roche’s antinausea drug, associated with cancer therapy drug, Kytril.

The generic, granisetron hydrochloride tablets will be available in a 1 mg dose and will be shipped immediately.

Kytril tablets had sales in the U.S. of about $89 million for the 12 months that ended Sept. 30, 2007, according to IMS Health.